Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
20 nov. 2024 07h00 HE
|
CYTOMED THERAPEUTICS LIMITED
SINGAPORE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Further to an announcement on October 7, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical...
Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company’s Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use
15 oct. 2024 11h36 HE
|
Tevogen Bio Inc
Tevogen Bio CEO Expresses Optimism About the Company’s Scientific Breakthrough in Mainstreaming Cell Therapy
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates
30 sept. 2024 07h00 HE
|
CYTOMED THERAPEUTICS LIMITED
Conference call via Zoom is scheduled for October 8, 2024 at 9 a.m. ET (9 p.m. SGT) https://us06web.zoom.us/meeting/register/tZMrcOmppj0sGdA37lASywTyixRflo9w1TZT SINGAPORE, Sept. 30, 2024 (GLOBE...
Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities
09 août 2024 11h00 HE
|
Tevogen Bio Inc
Tevogen Bio reaffirms that the registration statement does not relate to any previously undisclosed new issuances of dilutive securities.
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers
17 juil. 2024 07h00 HE
|
CYTOMED THERAPEUTICS LIMITED
SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary...
Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian
10 juil. 2024 08h05 HE
|
Tevogen Bio Inc
Dr. Flomenberg and Dr. Grosso are leading experts in T cell biology and its clinical applicationsTevogen’s ExacTcell™ platform is designed to address current cost, and patient accessibility...
Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference
18 juin 2024 15h17 HE
|
Tevogen Bio Inc
Untapped potential and development of a new class of T Cell therapies for large patient populations. Overcoming CAR-T challenges.
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
11 juin 2024 15h30 HE
|
Tevogen Bio Inc
Agreement for Up to $50 Million in Financing. Includes $36 million line of credit and potential $14 million private placement.
CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event
07 juin 2024 15h32 HE
|
Tevogen Bio Inc
Tevogen social event aimed to understand patients' needs and discuss how its model could reduce healthcare costs and improve patient outcomes.
Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event
06 juin 2024 18h14 HE
|
Tevogen Bio Inc
Tevogen social event aimed to understand patients' needs and discuss how its model could reduce healthcare costs and improve patient outcomes.